Envoy Medical holder discloses 84.8% stake

Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment.

Rhea-AI Filing Summary

Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment. He purchased 18,750,000 shares of Class A Common Stock together with Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares at a combined price of $0.40 per share and accompanying warrants, for an aggregate $7,500,000 funded with personal funds.

The common warrants have a $0.40 exercise price and become exercisable after stockholder approval of the warrant share issuance, with Series A-1 Warrants expiring up to 24 months after that approval (or earlier upon Milestone 1) and Series A-2 Warrants up to 60 months (or earlier upon Milestone 2). As of February 12, 2025, he is treated as beneficially owning 68,909,614 shares of Class A Common Stock, or 84.8% of the class, based on 76,881,110 shares outstanding immediately following the company’s offering, including the warrant shares. On the same date, he directly holds 29,040,049 outstanding shares, or 37.7% of those outstanding shares.

Insights

Equity ownership and governance analyst

Large existing stockholder formalizes an 84.8% beneficial stake via new shares and warrants.

Glen A. Taylor documents a sizable participation in an Envoy Medical offering, buying 18,750,000 Class A shares plus common warrants for $7,500,000 at $0.40 per share-and-warrant unit, funded with personal capital. This aligns his economic exposure with other investors in the same financing terms.

Including the new warrant positions, he is treated as beneficially owning 68,909,614 shares, or 84.8% of Class A Common Stock, based on 76,881,110 shares outstanding immediately after the offering. The filing clarifies that warrant shares are counted for beneficial ownership even though they become exercisable only after stockholder approval.

Excluding the warrants, Taylor directly holds 29,040,049 outstanding shares, or 37.7% of the post-offering Class A total. The amendment also states he has sole voting and dispositive power over these shares. Subsequent company disclosures may further detail any stockholder approval timing that governs when the warrants can actually be exercised.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Envoy Medical (COCH) stockholder Glen A. Taylor report in this Schedule 13D/A?

Glen A. Taylor reports updated beneficial ownership of Envoy Medical Class A Common Stock following a February 2026 offering. He discloses new share and warrant purchases, total beneficial holdings, and confirms his sole voting and dispositive power over the reported securities.

How many Envoy Medical (COCH) shares and warrants did Glen A. Taylor purchase?

Taylor purchased 18,750,000 shares of Class A Common Stock plus Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares. All were acquired in the company’s offering described in the February 11, 2026 prospectus filed with the SEC on February 12, 2026.

What price did Glen A. Taylor pay in the Envoy Medical (COCH) offering and how was it funded?

He paid a combined offering price of $0.40 for each share of Class A Common Stock and its accompanying common warrants, for a total purchase price of $7,500,000. The filing states this aggregate amount was funded entirely with his personal funds.

What is Glen A. Taylor’s beneficial ownership percentage in Envoy Medical (COCH) after this transaction?

The amendment states Taylor beneficially owns 68,909,614 shares of Class A Common Stock, representing 84.8% of the class. This percentage is calculated using 76,881,110 shares outstanding immediately after the company’s offering, as disclosed in Envoy Medical’s February 11, 2026 prospectus.

How much Envoy Medical (COCH) stock does Glen A. Taylor hold excluding warrant shares?

As of February 12, 2025, Taylor holds 29,040,049 shares of Envoy Medical Class A Common Stock that are outstanding. This represents 37.7% of the 76,881,110 outstanding shares immediately following the offering, separate from any shares underlying the common warrants.

When do Glen A. Taylor’s Envoy Medical (COCH) warrants become exercisable and when do they expire?

The common warrants have a $0.40 exercise price and become exercisable on the effective date of stockholder approval of the warrant share issuance. Series A-1 Warrants expire up to 24 months after that approval or 30 days after Milestone 1, while Series A-2 Warrants expire up to 60 months or 30 days after Milestone 2.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 09:14 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Envoy Medical, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

29415V109

(CUSIP Number)

Brian A. Mayer, Esq.
Taylor Corporation, 1725 Roe Crest Drive
North Mankato, MN, 56003
507.386.3193

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 29415V109

1

Name of reporting person

Glen A. Taylor

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 68,909,614.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 68,909,614.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

68,909,614.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

84.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock
(b)	Name of Issuer: Envoy Medical, Inc.
(c)	Address of Issuer's Principal Executive Offices: 4875 White Bear Parkway, White Bear Lake, MINNESOTA , 55110.
Item 1 Comment: This Amendment No. 1 to Schedule 13D (this "Amendment") is being filed by Glen A. Taylor (the "Reporting Person") to amend and supplement certain Items of that the Schedule 13D filed with the Securities and Exchange Commission ("SEC") on December 8, 2025 (the "Original Schedule 13D"). Information contained in the Original Schedule 13D, remains effective except to the extent that it is amended, restated, supplemented, or superseded by the information contained in this Amendment. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Original Schedule 13D is hereby amended by adding the following as the last paragraph thereof: On February 12, 2026, the Reporting Person purchased in the offering described in Envoy Medical, Inc.'s (the "Company") Prospectus dated February 11, 2026 (filed with the SEC on February 12, 2026), 18,750,000 shares of Class A Common Stock and Series A-1 Warrants to purchase 11,250,000 shares of Class A Common Stock (the "Series A-1 Warrants") and Series A-2 Warrants to purchase 18,750,000 shares of Class A Common Stock (the "Series A-2 Warrants" and collectively, with the Series A-1 Warrants, the "Common Warrants"). For each share of Class A Common Stock purchased, the Reporting Person received accompanying Common Warrants in the amount of six-tenths (0.6) of a Series A-1 Warrant and one Series A-2 Warrant. The combined offering price for each share of Class A Common Stock and accompanying Common Warrants was $0.40. The aggregate purchase price of the Class A Common Stock and accompanying Common Warrants purchased by the Reporting Person was $7,500,000 which was funded with personal funds. The Common Warrants have an exercise price of $0.40 per share of Class A Common Stock and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants ("Stockholder Approval Date"). The Series A-1 Warrants will expire on the earlier of the 24-month anniversary of the Stockholder Approval Date or 30 days following the occurrence of Milestone 1 (as defined in the Series A-1 Warrant). The Series A-2 Warrants will expire on the earlier of the 60-month anniversary of the Stockholder Approval Date or 30 days following the occurrence of Milestone 2 (as defined in the Series A-2 Warrant). The Reporting Person purchased the Class A Common Stock and Common Warrants at the same purchase price per share and on the same terms as other investors in the offering.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 is hereby amended to read as follows: The information set forth in the cover pages and Item 3 of this Schedule 13D are incorporated herein by reference. As of February 12, 2025, the Reporting Person beneficially owns an aggregate of 68,909,614 shares of Class A Common Stock, which represents 84.8% of the Class A Common Stock based upon an aggregate of 76,881,110 shares of Class A Common Stock outstanding immediately following the Company's offering, as reported in the Company's Prospectus dated February 11, 2026, filed with the SEC on February 12, 2026. Although the Common Warrants are exercisable only after the Stockholder Approval Date such that the Reporting Person may not have a right to acquire the Class A Common Stock underlying the Common Warrants within 60 days, for the purposes of this Amendment, the shares of Class A Common Stock underlying the Common Warrants are treated as beneficially owned by the Reporting Person. As of February 12, 2025, the Reporting Person holds an aggregate of 29,040,049 shares of Class A Common Stock, which represents 37.7% of the 76,881,110 shares of Class A Common Stock outstanding immediately following the Company's offering.
(b)	The Reporting Person has sole voting and sole dispositive power over all shares beneficially owned.
(c)	Except as reported in this Amendment, the Reporting Person has not made any transactions in the Company's securities within the prior 60 days.
(d)	None.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 is hereby is hereby amended by adding the following as the last paragraph thereof: Information with respect to the Common Warrants purchased by the Reporting Person on February 12, 2026 is incorporated herein by reference to Item 3 and to the respective forms of the Series A-1 Warrant and Series A-2 Warrant incorporated by reference in Item 7 hereof.
Item 7.	Material to be Filed as Exhibits.
	Item 7 is hereby is hereby amended by adding the following exhibits: Exhibit 2 Form of Series A-1 Warrant issued by Envoy Medical, Inc. on February 12, 2026 (incorporated by reference to Exhibit 4.10 to the Company's Registration Statement on Form S-1/A (SEC File No. 333-292260) filed on February 6, 2026). Exhibit 3 Form of Series A-2 Warrant issued by Envoy Medical, Inc. on February 12, 2026 (incorporated by reference to Exhibit 4.11 to the Company's Registration Statement on Form S-1/A (SEC File No. 333-292260) filed on February 6, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glen A. Taylor

Signature:	/s/ Glen Taylor
Name/Title:	Glen A. Taylor
Date:	02/16/2026